台湾温抗体型自身免疫性溶血性贫血的流行病学、治疗模式、生存与医疗利用(2017-2022)
基于台湾全民健康保险研究数据库等回顾性识别2017-2022年接受wAIHA相关治疗的成人患者,描述其流行病学、治疗模式、总生存与医疗资源使用。wAIHA发病率为1.27/10万人年,2022年患病率为4.58/10万人;糖皮质激素单药为各线最常见治疗,诊断2年后仍有30.2%患者使用糖皮质激素;5年OS概率为67.1%。
要点
- wAIHA发病率1.27/10万人年,2022年患病率4.58/10万人。
- 糖皮质激素单药为各线最常见治疗,诊断2年后30.2%患者仍使用。
- 5年OS概率67.1%,诊断首年52.5%患者至少接受一次紧急输血。
核心结论
- 台湾wAIHA管理仍存在显著未满足医疗需求,包括长期依赖糖皮质激素、总生存欠佳及高医疗服务使用。
研究设计与样本
- 回顾性研究,从台湾全民健康保险研究数据库链接死亡登记与癌症登记,识别2017-2022年有AIHA诊断码且记录wAIHA相关治疗的成人患者。
主要发现
- wAIHA发病率为1.27/10万人年,2022年患病率为4.58/10万人。
- 糖皮质激素单药为各线最常见治疗,诊断2年后30.2%患者仍使用糖皮质激素。
- 诊断首年52.5%患者至少接受一次紧急输血。
- Kaplan-Meier分析估计5年OS概率为67.1%。
关键数值与推荐
- 重症监护室入住是主要费用驱动因素,广义线性模型(伽马分布、对数链接)调整后指数系数为2.76(95%CI:2.26-3.36)。
临床怎么用
- 应关注wAIHA患者长期糖皮质激素依赖及高输血需求,优化治疗策略以改善生存并降低医疗资源使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To describe the epidemiology, treatment patterns, overall survival (OS) and healthcare resource use among patients with warm autoimmune haemolytic anaemia (wAIHA) in Taiwan, adult patients with ≥1 diagnosis code for autoimmune haemolytic anaemia (AIHA) with record of wAIHA-related treatments between 2017 and 2022 were retrospectively identified from Taiwan's National Health Insurance Research Database linked with the National Death Registry and Taiwan Cancer Registry. The wAIHA incidence was 1.27 per 100 000 person-years, and the 2022 prevalence was 4.58 per 100 000 persons. Corticosteroid monotherapy was the most common treatment across all lines, with 30.2% of patients remaining on corticosteroids 2 years after diagnosis. Blood transfusions were common in the first year following diagnosis, with 52.5% of patients receiving at least one emergency transfusion. The 5-year OS probability, estimated using Kaplan-Meier analysis, was 67.1%. The median annualised medical cost was NT$ (New Taiwan dollar) 106 464 (interquartile range [IQR]: 49 088-285 856) or US$ (US dollar) 3327 (IQR: 1534-8933). Intensive care unit admissions were the primary cost driver (adjusted exponentiated coefficient: 2.76 [95% confidence interval: 2.26-3.36]), determined using a generalised linear model with a gamma distribution and log link function. Overall, significant unmet medical needs remain for wAIHA management in Taiwan, including addressing prolonged reliance on corticosteroids, sub-optimal OS outcomes and high medical service use.
引用
- Kao HW, Chang SC, Yu DY, et al. Warm autoimmune haemolytic anaemia in Taiwan: A population-based study of epidemiology, treatment patterns, survival and healthcare utilisation (2017-2022). Br J Haematol. 2026. PMID: 42833886. doi:10.1111/bjh.70792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。